The oncology and immuno-oncology drug discovery landscape is evolving rapidly. Advances in molecular biology, genomics and immune science have enabled targeted therapies, immunotherapies and novel modalities such as protein degraders, antibody-based therapeutics and cell- and gene-based approaches. These innovations are reshaping cancer treatment while creating new scientific and translational challenges.
Cancer is highly heterogeneous, driven by complex molecular networks, adaptive resistance mechanisms and dynamic tumor–immune interactions. Translating promising concepts into viable drug candidates requires deep biological insight, robust experimental systems and tightly integrated discovery strategies.
We support oncology and immuno-oncology programs with end-to-end preclinical discovery solutions designed to help partners navigate biological complexity, reduce development risk and accelerate confident decision-making.
Our oncology and immuno-oncology capabilities are designed to evaluate and advance a wide range of therapeutic strategies, including:
From oncogenic signaling pathways to immune activation and tumor-microenvironment modulation, our scientific teams deliver mechanism-informed solutions tailored to each program’s objectives.
We offer extensive expertise across oncology-relevant target classes, including:
Our assay strategies integrate biochemical, biophysical ↗, cellular and phenotypic approaches ↗, enabling evaluation of target engagement ↗, functional activity ↗ and pathway modulation ↗. Translationally relevant cellular systems help bridge early discovery findings to downstream biological outcomes.
Traditional siloed discovery approaches may not capture the full biological complexity of cancer. Our model emphasizes integration across disciplines, combining biology, pharmacology and translational science to guide programs from early hypothesis through candidate selection.
Key elements of our integrated approach include:
This holistic framework helps identify risks early, prioritize promising assets and improve overall program efficiency.
What differentiates our oncology and immuno-oncology offering is the depth of scientific experience behind it.
Our teams include scientists and project leaders with extensive backgrounds in oncology research and drug discovery across pharmaceutical, biotechnology and academic environments. This experience translates into:
We work collaboratively with partners as an extension of their discovery teams, aligning scientific strategy, timelines and decision points from the outset.
To support informed progression decisions, we design tailored preclinical studies that integrate:
Our translational mindset ensures that preclinical data are decision-enabling, supporting downstream development planning while remaining rooted in discovery-stage objectives.
At the core of our approach is a commitment to rigorous science, thoughtful integration and practical impact. Cancer is not a single disease, and effective therapies often emerge at the intersection of oncology, immunology and broader disease biology.
By combining cross-disciplinary expertise with flexible discovery platforms, we help partners move from innovative ideas to high-quality drug candidates with confidence.
Whether you are exploring a novel oncology target, advancing an immuno-oncology concept or optimizing a complex therapeutic modality, we offer the expertise, infrastructure and collaborative mindset to support your program.
Together, we help turn scientific insight into meaningful oncology drug discovery progress.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
Get a quote
Go top
